ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, has been rated as one of the top-performing contract research organisations (CRO) for phase 1 clini ...

NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the “Company”), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic ...

MSD unveiled the launch of the Phase III trials of MK-8527 at the International AIDS Society (IAS) 2025 conference.

Biotech company CRISPR Therapeutics has a market cap of around $5 billion, but it has the potential to be much more valuable ...

Company aims for technology advancement and platform expansion with Korea's first influenza vaccine using an adjuvant Interim ...

In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a ...

Rahway, New Jersey Wednesday, July 16, 2025, 17:30 Hrs [IST] ...

Verastem Oncology releases primary results from phase 2 RAMP 201 trial of Avutometinib in combo with defactinib: Boston Tuesday, July 15, 2025, 09:00 Hrs [IST] Verastem Oncology, ...

Kester Capital-backed Evestia Clinical merges with US-based Atlantic Research Group (ARG) to create a leading independent global specialist CRO in fast-growing marketsThe merger delivers on Evestia ...

Supporters believe that FDA approval will make the drug more accessible. Right now, traditional psilocybin therapy offered at healing centers in the state is not covered by insurance.

University of New Mexico researchers have received funding to launch an early-stage clinical trial of a vaccine engineered to ...